Physician profile
Vishva Dev
NPI 1770513723
$21,784.87
in general payments reported to CMS, 2019-2025
30 companies · $6,076 in 2025
The $6,076 reported for 2025 was more than what 85% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,470 · 2020: $1,885 · 2021: $2,921 · 2022: $1,314 · 2023: $1,461 · 2024: $4,658 · 2025: $6,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,915 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,914.55 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,280.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $7,690.83 | 2021-2025 | Corevalve Evolut R, Affera Mapping System, Linq II |
| Abbott Laboratories | $4,922.95 | 2019-2025 | Navitor, Portico, Coroflow |
| Medtronic Vascular, INC. | $1,481.54 | 2019-2020 | |
| Boston Scientific Corporation | $1,358.60 | 2019-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Latitude Communicator Power Supply |
| Penumbra, INC. | $1,241.61 | 2021 | |
| Novartis Pharmaceuticals Corporation | $914.05 | 2021-2025 | |
| Abiomed | $903.19 | 2019-2025 | Impella |
| Amgen INC. | $683.13 | 2019-2025 | Repatha, Repatha |
| Biotronik INC. | $554.19 | 2022-2025 | Biomonitor, Amvia Edge, Acticor 7 Vr-T Dx |
| E.R. Squibb & Sons, L.L.C. | $326.75 | 2021-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $312.70 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $289.35 | 2021-2022 | |
| Esperion Therapeutics, INC. | $238.83 | 2020-2024 | Nexletol |
| Inari Medical, INC. | $183.06 | 2022 | |
| Cardiva Medical, INC. | $164.78 | 2022-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade Mvp Xl Vvcs 10-12f |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $75.31 | 2024 | |
| Becton, Dickinson and Company | $59.49 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $58.20 | 2021-2024 | Livalo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $55.62 | 2023-2024 | Lifevest |
| Edwards Lifesciences Corporation | $53.47 | 2019 | |
| Novo Nordisk INC | $33.09 | 2025 | Wegovy |
| Cordis US Corp. | $29.22 | 2024 | Selution Slrpta |
| Alnylam Pharmaceuticals INC. | $27.38 | 2025 | Amvuttra |
| Azurity Pharmaceuticals, INC. | $26.74 | 2025 | Edarbi |
| Biosense Webster, INC. | $20.40 | 2021 | |
| W. L. Gore & Associates, INC. | $18.61 | 2024 | Gore Cardioform Septal Occluder |
| Ekos Corporation | $17.67 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.15 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $15.29 | 2024 | Arcalyst |
| Gilead Sciences, INC. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vishva Dev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.